Open Nav

Please submit your session questions in advance at http://bit.ly/BIOCEO19question

Summit Therapeutics

  • Glyn Edwards, Summit Therapeutics

Summit Therapeutics is a leader in antibiotic innovation. Our new mechanism antibiotics are designed to become the new standards of care for the benefit of patients and create value for payors and healthcare providers. We are currently developing new mechanism antibiotics for infections caused by C. difficile. N. gonorrhoeae and ESKAPE pathogens and are using our proprietary Discuva Platform to expand our pipeline.

  • Date:Monday, February 11
  • Time:10:00 AM - 10:15 AM
  • Room:Hudson/Empire
  • Location:7th Floor
  • Session Type:Company Presentation
  • Please submit your session questions in advance at:http://bit.ly/BIOCEO19question
  • Company Presentation - Presentation Type:Publicly Traded Company
  • Submission ID:23306
  • Goal for Presentation:Increase awareness
  • Company Website:www.summitplc.com
  • Company HQ City:Abingdon
  • Company HQ Country:United Kingdom
  • Ticker:SMMT
  • Exchange:Nasdaq
  • CEO/Top Company Official:Glyn Edwards
  • Main Therapeutic Focus:Infectious Diseases
  • Lead Product in Development:Ridinilazole
  • Development Phase of Primary Product:Phase III
Speakers
Glyn Edwards
Summit Therapeutics
Back